Medtech grants in France

Scheduled

Funds €7–9M projects taking biomarker-guided rare-cancer treatments into first-in-human, multicentre phase 1 trials.

Scheduled

Funds €7–8M projects that use functional genomics and patient data to uncover precise new targets for difficult-to-treat cancers.

Scheduled

Funds €7–10M programmes that bring better cancer diagnosis and treatment trials to patients across four or more European countries.

Scheduled

Funds three €5–7M projects that make cancer control more equitable, effective and cost-aware for patients and families.

Scheduled

Funds two €12M projects using living labs to remediate carcinogenic soils and trace cancer risks through people, food, water and air.

Scheduled

Funds €8–10M procurer consortia to bring affordable cancer technologies, devices and medicines from tender to patient benefit.

Scheduled

Funds one €3M coordination action that helps cancer charities and funders improve quality of life for young survivors across Europe.

Scheduled

Funds €7–10M projects that advance living-cell bio-printing from laboratory proof toward regenerative medicine.

Scheduled

Funds €10–12M projects that make Virtual Human Twins useful for prevention, diagnosis and safer clinical decisions.

Scheduled

Funds a European community and roadmap for trustworthy frontier AI models in healthcare.

Between cycles

Funds research consortia developing biotechnology-based interventions, biomarkers or non-animal test methods that target the root causes of age-related disease.

Between cycles

Funds late stage deep tech start ups and small businesses with combined non dilutive and growth support across technology fields.

Between cycles

Invests in scale-up ventures in digital, clean technology, and biotechnology through equity to accelerate commercialization pathways.

Between cycles

Funds innovative SME-led international R&D consortia through the Eurostars Call 12 grant process.

Between cycles

Funds a research consortium that studies why immune-mediated diseases behave differently when they first strike older adults and hunts for biomarkers to predict them.

Between cycles

Supports ARPA inspired high risk demand driven pilots translating new approach methods into practical deep tech practice.

Between cycles

Runs students and early career scholars with mentoring support for CRF Postdoctoral Research Fellowship in biotechnology, medical technology, and synthetic biology.

Between cycles

Administers research teams and institutions for CRF Research Grant in biotechnology, medical technology, and synthetic biology.

Between cycles

Supports EIC beneficiaries' participation in major trade fairs across the EU, MENA and the US.

Between cycles

Funds early-stage deep tech startups developing solutions at TRL 4-5 in collaboration with industry partners through a 4-month co-creation programme.

Between cycles

Runs research teams and institutions for EIT Health Catapult Edition in biotechnology, medical technology, and artificial intelligence.

Between cycles

Funds early-career researchers building an independent research team and pursuing frontier research through an ERC Starting Grant hosted at a public or private research organisation.

Between cycles

Funds a €7M platform giving adolescent and young adult cancer patients and survivors personalized digital tools for coping and psychological support.

Between cycles

Funds a €15M project that turns microbiome signals into a test for spotting cancer risk years ahead of any symptoms.